- Home
- AXSM vs CWAN Comparison
AXSM vs CWAN Comparison
Compare AXSM & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXSM
- CWAN
- Stock Information
- Founded
- AXSM 2012
- CWAN 2004
- Country
- AXSM United States
- CWAN United States
- Employees
- AXSM N/A
- CWAN N/A
- Industry
- AXSM Biotechnology: Pharmaceutical Preparations
- CWAN Computer Software: Prepackaged Software
- Sector
- AXSM Health Care
- CWAN Technology
- Exchange
- AXSM Nasdaq
- CWAN Nasdaq
- Market Cap
- AXSM 5.1B
- CWAN 6.1B
- IPO Year
- AXSM 2015
- CWAN 2021
- Fundamental
- Price
- AXSM $108.98
- CWAN $21.77
- Analyst Decision
- AXSM Strong Buy
- CWAN Buy
- Analyst Count
- AXSM 17
- CWAN 10
- Target Price
- AXSM $171.65
- CWAN $31.50
- AVG Volume (30 Days)
- AXSM 636.2K
- CWAN 4.1M
- Earning Date
- AXSM 08-04-2025
- CWAN 07-30-2025
- Dividend Yield
- AXSM N/A
- CWAN N/A
- EPS Growth
- AXSM N/A
- CWAN N/A
- EPS
- AXSM N/A
- CWAN 1.71
- Revenue
- AXSM $432,157,000.00
- CWAN $475,948,000.00
- Revenue This Year
- AXSM $62.84
- CWAN $63.43
- Revenue Next Year
- AXSM $60.02
- CWAN $29.94
- P/E Ratio
- AXSM N/A
- CWAN $12.75
- Revenue Growth
- AXSM 72.16
- CWAN 23.21
- 52 Week Low
- AXSM $72.21
- CWAN $17.94
- 52 Week High
- AXSM $139.13
- CWAN $35.71
- Technical
- Relative Strength Index (RSI)
- AXSM 56.00
- CWAN 44.69
- Support Level
- AXSM $102.26
- CWAN $21.39
- Resistance Level
- AXSM $114.66
- CWAN $22.92
- Average True Range (ATR)
- AXSM 3.49
- CWAN 0.65
- MACD
- AXSM 0.92
- CWAN 0.06
- Stochastic Oscillator
- AXSM 61.89
- CWAN 45.33
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.